Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti

English version České info

Background:
In a randomized clinical trial of early versus standard antiretroviral therapy (ART) in HIV-infected adults with a CD4 cell count between 200 and 350 cells/mm³ in Haiti, early ART decreased mortality by 75%. We assessed the cost-effectiveness of early versus standard ART in this trial.

Methods and Findings:
Trial data included use of ART and other medications, laboratory tests, outpatient visits, radiographic studies, procedures, and hospital services. Medication, laboratory, radiograph, labor, and overhead costs were from the study clinic, and hospital and procedure costs were from local providers. We evaluated cost per year of life saved (YLS), including patient and caregiver costs, with a median of 21 months and maximum of 36 months of follow-up, and with costs and life expectancy discounted at 3% per annum. Between 2005 and 2008, 816 participants were enrolled and followed for a median of 21 months. Mean total costs per patient during the trial were US$1,381 for early ART and US$1,033 for standard ART. After excluding research-related laboratory tests without clinical benefit, costs were US$1,158 (early ART) and US$979 (standard ART). Early ART patients had higher mean costs for ART (US$398 versus US$81) but lower costs for non-ART medications, CD4 cell counts, clinically indicated tests, and radiographs (US$275 versus US$384). The cost-effectiveness ratio after a maximum of 3 years for early versus standard ART was US$3,975/YLS (95% CI US$2,129/YLS–US$9,979/YLS) including research-related tests, and US$2,050/YLS excluding research-related tests (95% CI US$722/YLS–US$5,537/YLS).

Conclusions:
Initiating ART in HIV-infected adults with a CD4 cell count between 200 and 350 cells/mm³ in Haiti, consistent with World Health Organization advice, was cost-effective (US$/YLS <3 times gross domestic product per capita) after a maximum of 3 years, after excluding research-related laboratory tests.

Trial registration:
ClinicalTrials.gov NCT00120510

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti. PLoS Med 8(9): e32767. doi:10.1371/journal.pmed.1001095
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001095

Souhrn

Trial registration:
ClinicalTrials.gov NCT00120510

: Please see later in the article for the Editors' Summary

Zdroje

1. World Health Organization 2009 Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Available: http://www.who.int/hiv/pub/arv/advice/en/index.html. Accessed 14 May 2010

2. SeverePJean JusteMAAmbroiseAEliacinLMarchandC 2010 Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 363 257 265

3. EmerySNeuhausJAPhillipsANBabikerACohenCJ 2008 Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197 1133 1144

4. World Health Organization 2010 Towards universal access: scaling up priority HIV/AIDS interventions in the health sector - progress report 2010. Available: http://www.who.int/hiv/pub/2010progressreport/report/en/index.html. Accessed 4 March 2011

5. Republique d'Haiti Programme National de Lutte contre le Sida 2010 Rapport de situation nationale à l' intention de l'UNGASS. Available: http://data.unaids.org/pub/Report/2010/haiti_2010_country_progress_report_fr.pdf. Accessed 14 May 2010

6. UNAIDS 2010 AIDSinfo database. Available: http://www.aidsinfoonline.org/. Accessed 20 January 2010

7. KoenigSPRiviereCLegerPSeverePAtwoodS 2008 The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc 6 3

8. SeverePLegerPCharlesMNoelFBonhommeG 2005 Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353 2325 2334

9. Oanda Corporation 2009 FX history: historical currency exchange rates. Available: http://www.oanda.com/currency/historical-rates. Accessed 14 May 2010

10. World Health Organization 2009 Global price reporting mechanism. Available: http://apps.who.int/hiv/amds/price/hdd/index.aspx. Accessed 14 May 2010

11. International Dispensary Association Foundation 2009 International Dispensary Association Foundation. Available: http://www.ida.nl/. Accessed 14 May 2010

12. International Monetary Fund Western Hemisphere Department 2009 International Monetary Fund country report number 09/258. Available: http://www.imf.org/external/pubs/ft/scr/2009/cr09258.pdf. Accessed 14 May 2010

13. PetrouSBischofMBennettCElbourneDFieldD 2006 Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial. Pediatrics 117 1640 1649

14. GlickHDoshiJSonnadSPolskyD 2007 Economic evaluation in clinical trials Oxford Oxford University Press 244

15. ZhaoHBangHWangHPfeiferPE 2007 On the equivalence of some medical cost estimators with censored data. Stat Med 26 4520 4530

16. ZhaoHTianL 2001 On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics 57 1002 1008

17. HuangY 2009 Cost analysis with censored data. Med Care 47 S115 119

18. Tan-Torres EdejerTBaltussenRAdamTHutubessyRAcharyaA 2003 Making choices in health: WHO guide to cost-effectiveness analysis Geneva WHO

19. PetrouSGrayA 2011 Economic evaluation alongside randomized controlled trials: design, conduct, analysis, and reporting. BMJ 342 d15487

20. CairnsJ 2001 Discounting in economic evaluation. DrummondMFMcGuireA Economic evaluation in health care New York Oxford University Press Inc 236 255

21. BriggsAHGrayAM 1999 Handling uncertainty in economic evaluations of healthcare interventions. BMJ 319 635 638

22. FiellerEC 1954 Some problems in interval estimation. J R Stat Soc Series B Stat Methodol 16 175 185

23. MugyenyiPWalkerASHakimJMunderiPGibbDM 2010 Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375 123 131

24. Koenig SerenaPSchackman BruceRRiviereCLegerPCharlesM 2010 Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource poor setting. Clin Infect Dis 51 600 608

25. World Health Organization 2010 Antiretroviral therapy for HIV infection in adults and adolescents recommendations for a public health approach 2010 revision Geneva WHO

26. HutubessyRBaltussenRTorres-EdejerTTEvansDB 2003 WHO-CHOICE: choosing interventions that are cost-effective. MurrayCJLEvansDB Health systems performance assessment: debates, methods and empiricism Geneva WHO Editions

27. WalenskyRPWolfLLWoodRFofanaMOFreedbergKA 2009 When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 151 157 166

28. FreedbergKAKumarasamyNLosinaECeceliaAJScottCA 2007 Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 21 Suppl 4 S117 128

29. International Monetary Fund 2009 World economic outlook database. Available: http://www.imf.org/external/pubs/ft/weo/2009/01/weodata/index.aspx. Accessed 14 May 2010

30. Medicins Sans Frontieres 2010 Untangling the web of antiretroviral price reductions. Available: http://utw.msfaccess.org/. Accessed 20 January 2011

31. GrasLKesselringAMGriffinJTvan SighemAIFraserC 2007 CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 45 183 192

32. KitahataMMGangeSJAbrahamAGMerrimanBSaagMS 2009 Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360 1815 1826

33. SterneJAMayMCostagliolaDde WolfFPhillipsAN 2009 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373 1352 1363

34. KelleyCFKitchenCMHuntPWRodriguezBHechtFM 2009 Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 48 787 794

35. MayMSterneJASabinCCostagliolaDJusticeAC 2007 Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 21 1185 1197

36. RobbinsGKSpritzlerJGChanESAsmuthDMGandhiRT 2009 Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 48 350 361

37. CastillaJDel RomeroJHernandoVMarincovichBGarciaS 2005 Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 40 96 101

38. LimaVDJohnstonKHoggRSLevyARHarriganPR 2008 Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 198 59 67

39. IngleSMMayMUebelKTimmermanVKotzeE 2010 Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS 24 2717 2725

40. LarsonBABrennanAMcNamaraLLongLRosenS 2010 Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health 15 Suppl 1 43 47

41. DrummondMFSculpherMJTorranceGWO'BrienBJStoddartGL 2005 Methods for the economic evaluation of health care programs. 3rd edition Oxford Oxford University Press

42. LoubiereSel FilalKMSodqiMLoundouALuchiniS 2008 When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience. Antivir Ther 13 241 251

43. BadriMClearySMaartensGPittJBekkerLG 2006 When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 11 63 72